Literature DB >> 29423383

Biodistribution of 99mTc-MAA on SPECT/CT performed for 90Y radioembolization therapy planning: a pictorial review.

J J Bailey1, Y Dewaraja1, D Hubers1, R N Srinivasa1, K A Frey1.   

Abstract

Purpose: To evaluate the frequency of 99mTc-MAA uptake in extrahepatic organs during 90Y radioembolization therapy planning.
Methods: This retrospective case series of 70 subjects who underwent 99mTc-MAA hepatic artery perfusion studies between January 2014 and July 2016 for 90Y radioembolization therapy planning at our institution involved direct image review for all subjects, with endpoints recorded: lung shunt fraction, extrahepatic radiotracer uptake, time from MAA injection to imaging.
Results: Combined planar and SPECT/CT imaging findings in the 70 subjects demonstrated lung shunt fraction measurements of less than 10% in 53 (76%) subjects and greater than 10% in 17 (24%) subjects. All patients demonstrated renal cortical uptake, 23 (33%) demonstrated salivary gland uptake, 23 (33%) demonstrated thyroid uptake, and 32 (46%) demonstrated gastric mucosal uptake, with significant overlap between these groups. The range of elapsed times between MAA injection and initial imaging was 41-138 min, with a mean of 92 min. There was no correlation between time to imaging and the presence of extrahepatic radiotracer uptake at any site. Conclusions: During hepatic artery perfusion scanning for 90Y radioembolization therapy planning, extrahepatic uptake is common, particularly in the kidney, salivary gland, thyroid and gastric mucosa, and is hypothesized to result from breakdown of 99mTc-MAA over time. Given the breakdown to smaller aggregates and ultimately pertechnetate, this should not be a contraindication to actual Y-90 microsphere therapy. Although we found no correlation between time to imaging and extrahepatic uptake, most of our injection to imaging times were relatively short.

Entities:  

Keywords:  Biodistribution; Hepatic artery perfusion sctinigraphy; Macroaggregated albumin Body:; Y90 radioembolization

Year:  2017        PMID: 29423383      PMCID: PMC5798624          DOI: 10.1007/s40336-017-0245-8

Source DB:  PubMed          Journal:  Clin Transl Imaging        ISSN: 2281-5872


  8 in total

1.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  Francesco Giammarile; Lisa Bodei; Carlo Chiesa; Glenn Flux; Flavio Forrer; Françoise Kraeber-Bodere; Boudewijn Brans; Bieke Lambert; Mark Konijnenberg; Françoise Borson-Chazot; Jan Tennvall; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07       Impact factor: 9.236

2.  Influence of time delay on the estimated lung shunt fraction on 99mTc-labeled MAA scintigraphy for 90Y microsphere treatment planning.

Authors:  Ruth De Gersem; Geert Maleux; Hubert Vanbilloen; Kristof Baete; Chris Verslype; Karin Haustermans; Alfons Verbruggen; Eric Van Cutsem; Christophe Michel Deroose
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

3.  Radiation-induced cholecystitis after hepatic radioembolization: do we need to take precautionary measures?

Authors:  Jip F Prince; Andor F van den Hoven; Maurice A A J van den Bosch; Mattijs Elschot; Hugo W A M de Jong; Marnix G E H Lam
Journal:  J Vasc Interv Radiol       Date:  2014-10-23       Impact factor: 3.464

Review 4.  From the angio suite to the γ-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization--a comprehensive pictorial review.

Authors:  Livnat Uliel; Henry D Royal; Michael D Darcy; Darryl A Zuckerman; Akash Sharma; Nael E Saad
Journal:  J Nucl Med       Date:  2012-11       Impact factor: 10.057

5.  Re: thyroid activity on technetium-99m macroaggregated albumin lung scans.

Authors:  R G Lee; T C Hill; A P Rolla; M E Clouse
Journal:  J Nucl Med       Date:  1983-08       Impact factor: 10.057

6.  Radiation absorbed dose from albumin microspheres labeled with technetium-99m. Task Group of the Medical Internal Radiation Dose Committee. The Society of Nuclear Medicine.

Authors:  M Blau; R Wicks; S R Thomas; K A Lathrop
Journal:  J Nucl Med       Date:  1982-10       Impact factor: 10.057

7.  Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization.

Authors:  Laurence Lenoir; Julien Edeline; Yann Rolland; Marc Pracht; Jean-Luc Raoul; Valérie Ardisson; Patrick Bourguet; Bruno Clément; Eveline Boucher; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

Review 8.  Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.

Authors:  Etienne Garin; Yan Rolland; Sophie Laffont; Julien Edeline
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

  8 in total
  3 in total

1.  Anomalous Branch of the Left Hepatic Artery With Pericardial, Diaphragmatic, Splenic and Gastric Supply During Selective Internal Radiotherapy (SIRT).

Authors:  Naushad H Karim; Jon Bell; Damian Mullan; Jeremy Lawrance; Pavan Najran
Journal:  Cureus       Date:  2021-12-12

2.  The value of 99mTc-MAA SPECT/CT for lung shunt estimation in 90Y radioembolization: a phantom and patient study.

Authors:  Jonathan D Allred; Jeremy Niedbala; Justin K Mikell; Dawn Owen; Kirk A Frey; Yuni K Dewaraja
Journal:  EJNMMI Res       Date:  2018-06-15       Impact factor: 3.138

3.  Analysis of failed therapy evaluations in radioembolization of primary and secondary liver cancers.

Authors:  Michael Köhler; Moritz Wildgruber; Max Masthoff; Philipp Schindler; Fabian Harders; Walter Heindel; Christian Wilms; Hartmut H Schmidt; Andreas Pascher; Lars Stegger; Kambiz Rahbar
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-06       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.